Markets

Palisade Bio Highlights PALI-2108 Clinical And Translational Findings In 5 ACG 2026 Presentations

Oct 12, 2026 · 08:09 AM ET· updated 49m ago

Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 developmentTwo presentations selected for

Why It Matters

Palisade Bio showed new research about their medicine PALI-2108. The research suggests the medicine reaches the right places and works the way they hoped.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

PALI1.55

+0.10 (+6.90%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.